SUMMIT, N.J.--(BUSINESS WIRE)--Lautus Pharmaceuticals, LLC announced today that it is re-launching the GlyDerm brand of physician-dispensed skin care products. The company will be presenting the line at the American Academy of Dermatology Annual Meeting in Denver Colorado, March 21-24 and the American Society of Aesthetic Plastic Surgery in San Francisco, April 24-29 as it works to re-establish top of mind brand awareness with dermatologists and plastic surgeons. Lautus, a privately held pharmaceutical company focused on the dermatology and aesthetics market, recently acquired the brand from BioZone Laboratories, Inc.
The GlyDerm skincare line is built around its esterified glycolic acid peels which are marketed for professional use and range in strength from 20-70%. Chemical peels, which include glycolic acid peels, rank as one of the most popular non-surgical cosmetic procedures in the US, with 1.2 million peels performed last year, according to the American Society of Plastic Surgeons.1 Physicians use glycolic acid peels to help their patients achieve a smoother skin texture and reduce the appearance of fine lines and wrinkles.
“Glycolic acid, a naturally derived alpha hydroxy acid, can be irritating to the skin, explains Lautus President and CEO Steve Bosacki. “GlyDerm peels are uniquely formulated with a proprietary form of esterified glycolic acid. Our unique esterification process creates a time-released delivery of glycolic acid allowing us to deliver gentle, full-potency glycolic acid without the unwanted irritation and clinical unpredictability of other glycolic formulations.” http://www.glydermusa.com/glycolic-science/
The original GlyDerm line was created by board-certified dermatologist Marvin E. Klein, M.D. and has been trusted by dermatologists and plastic surgeons for over 20 years. At the height of its popularity, GlyDerm was sold in 30 countries. Although the brand has been continuously sold since 1992, it has not been actively promoted for the past eight years.
“GlyDerm is the best glycolic acid product on the market,” says Patrick G. LePore, Chairman of Lautus. “Although the brand has been flying under the radar in the physician-dispensed aesthetics category, it has a loyal customer base from Beverly Hills to New York City because of its proven track record of safety and efficacy.” To increase brand awareness and drive sales, Lautus is developing a multi-faceted plan that includes a dedicated sales force, customer training and marketing support and a sampling program. “In addition to re-connecting with our existing customers and introducing the brand to new users, we’re developing new and innovative products like our Vitamin C Serum which uses QuSome® technology to encapsulate L-ascorbic acid allowing it to penetrate the skin to stimulate collagen synthesis and reduce the signs of aging,” says Mr. LePore. http://www.glydermusa.com/glycolic-science/
Patrick G. LePore is the former Chairman and CEO of generic drug company Par Pharmaceutical which was recently acquired by affiliates of TPG, a global investment firm. Steve Bosacki is the former Senior Vice President and General Counsel for Oceana Therapeutics, a pharmaceutical company focused on the gastroenterology space, which was recently acquired by Salix Pharmaceuticals. The two first collaborated at Boron LePore and Associates, which specialized in providing outsourced promotional, marketing and education services to the pharmaceutical industry and was acquired by Cardinal Health.
About Lautus Pharmaceuticals, LLC
Lautus Pharmaceuticals, LLC is a privately held pharmaceutical company headquartered in Summit, NJ. Lautus is dedicated to providing safe, effective and innovative products that promote and maintain beautiful and healthy skin.
Lautus Pharmaceuticals, LLC, 129 Summit Avenue, Summit, NJ 07901, (908) 273-2777, www.GlyDermUSA.com